Eylea

FDA approves 'breakthrough' therapy for diabetic eye disorder

By

The FDA announced Wednesday that it has granted "breakthrough therapy designation" to the drug Eylea, and expanded its approved use for the treatment of diabetic retinopathy in patients with diabetic macular edema.